Overview

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This study will use Continuous Glucose Monitoring to assess differences in glycemic profiles between vildagliptin and glimepiride.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Glimepiride
Vildagliptin